Bello-Chavolla Omar Y, Rojas-Martinez Rosalba, Aguilar-Salinas Carlos A, Hernández-Avila Mauricio
R. Rojas-Martinez and M. Hernández-Avila are with the Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico. O.Y. Bello-Chavolla and C.A. Aguilar-Salinas are with the Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. O.Y. Bello-Chavolla is also the Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Nutr Rev. 2017 Jan;75(suppl 1):4-12. doi: 10.1093/nutrit/nuw030.
Type 2 diabetes is the main health problem in Mexico. The large and growing number of cases and the remarkable economic impact of the disease support this statement. The condition is expressed at an earlier age and at a lower body mass index in Mexican mestizos compared with the age and body mass index reported in Caucasians. In addition, Mexican mestizos have an increased susceptibility to developing diabetic nephropathy. The Mexican health system needs major adjustments in order to prevent and treat type 2 diabetes. Treatment is not currently based on the needs and expectations of the patient. As a result, it is insufficient, belated, and costly. Close to 20% of the preventable deaths in Mexico are caused by diabetes and related metabolic diseases. Even a small decrease in this rate could result in substantial savings for the Mexican healthcare system.
2型糖尿病是墨西哥主要的健康问题。大量且不断增加的病例以及该疾病显著的经济影响都支持这一说法。与高加索人报告的年龄和体重指数相比，墨西哥混血儿患2型糖尿病的年龄更小，体重指数更低。此外，墨西哥混血儿患糖尿病肾病的易感性增加。墨西哥卫生系统需要进行重大调整，以预防和治疗2型糖尿病。目前的治疗并非基于患者的需求和期望。因此，治疗不充分、延迟且成本高昂。墨西哥近20%的可预防死亡是由糖尿病和相关代谢疾病造成的。即使这一比率稍有下降，也能为墨西哥医疗系统节省大量资金。
